Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003748 · ClinicalTrials.gov registry record · Phase 2
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT00003748: Completed Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Jonsson Comprehensive Cancer Center.
NCT00003748 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003748, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
Study Locations (20)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- St Jude Heritage Health Foundation - Fullerton
- Daniel Freeman Memorial Hospital - Inglewood
- UCLA - Antelope Valley Cancer Center - Lancaster
- Pacific Shores Medical Group - Long Beach
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Community Hospital of the Monterey Peninsula - Monterey
- Office of Jerome L. Rubin - Monterey
- Office of Eddie Hu, M.D. - Monterey Park
- Ventura County Hematology-Oncology Medical Group, Inc. - Oxnard
- Wilshire Oncology Medical Center - Pomona
- Salinas Valley Memorial Hospital - Salinas
- Cancer Center of Santa Barbara - Santa Barbara
- Sansum Medical Clinic - Santa Barbara
- James L. Poth, M.D., Michael Alexander, M.D., Inc. - Santa Cruz
- Marian Medical Center - Santa Maria
- Office of Marilou Terpenning - Santa Monica
- Office of Robert C. Klein - Santa Monica
- Dominican and Watsonville Community Hospital - Soquel
- Los Robles Regional Medical Center - Thousand Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1998-08 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00003748 record still lists
NCT00003748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which irinotecan hydrochloride is the first listed.
NCT00003748 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT00003748 about?
NCT00003748 is a clinical study titled "Irinotecan in Treating Patients With Esophageal or Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.
What is the current status of trial NCT00003748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1998-08. Estimated completion is 2005-01.
What conditions does trial NCT00003748 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00003748?
The interventions under investigation include: irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003748?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003748 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003748's enrollment target sits among peer trials
40 128th of 153 higher than 22 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia